Survodutide

Survodutide is a dual glucagon and GLP-1 receptor agonist co-developed by Zealand Pharma and Boehringer Ingelheim. Currently under clinical investigation, it shows tremendous promise in treating obesity and MASH (liver disease) by increasing energy expenditure and reducing appetite.